key: cord-0712778-3t4vv50z authors: Wang, Zhijun; Jin, Li; Węgrzyn, Alicja title: Leptospirosis vaccines date: 2007-12-11 journal: Microb Cell Fact DOI: 10.1186/1475-2859-6-39 sha: 7d7dbaff8c306dacea117552f6c97cb0b2b79ce3 doc_id: 712778 cord_uid: 3t4vv50z Leptospirosis is a serious infection disease caused by pathogenic strains of the Leptospira spirochetes, which affects not only humans but also animals. It has long been expected to find an effective vaccine to prevent leptospirosis through immunization of high risk humans or animals. Although some leptospirosis vaccines have been obtained, the vaccination is relatively unsuccessful in clinical application despite decades of research and millions of dollars spent. In this review, the recent advancements of recombinant outer membrane protein (OMP) vaccines, lipopolysaccharide (LPS) vaccines, inactivated vaccines, attenuated vaccines and DNA vaccines against leptospirosis are reviewed. A comparison of these vaccines may lead to development of new potential methods to combat leptospirosis and facilitate the leptospirosis vaccine research. Moreover, a vaccine ontology database was built for the scientists working on the leptospirosis vaccines as a starting tool. Leptospirosis is a widespread disease [1] , caused by infection with the spirochete bacterium Leptospira, which affects almost all mammals [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Leptospirosis was initially described as Weil's syndrome [8, 14] . It is predominantly an occupational disease which affects humans who come into frequently contact with rodents, pets or polluted water [15] [16] [17] [18] (Fig. 1) . Infection is facilitated with penetrating leptospires through mucosa or an open skin [19] . After gaining entry through the skin, the bacterium causes a serious disease [19] . The symptoms of leptospirosis are extremely broad from meningitis [20] , pneumonitis [21, 22] , hepatitis [23] , nephritis [24] [25] [26] [27] , pancreatitis [28] and erythema nodosum [29] and death [30, 31] . ing this time, about 1,500 infected cases and 50 dead were reported. However, many human leptospirosis cases might be misdiagnosed or omitted due to poor medical care and information. Leptospira has over 200 pathogenic serovars, and divides into 25 serogroups, and many different strains with small antigenic differences can be found in some serovars [2, 17] . Leptospires have evolved ways to escape the immune defense. Pathogenic leptospires are able to translocate through cell monolayers at a rate significantly greater than that of nonpathogenic leptospires [32] . The rapid translocation of pathogenic leptospires between mammalian cells allows the bacteria to quickly reach the bloodstream and disseminate to multiple organs [32] . Virulent leptospires can rapidly enter kidney fibroblasts and induce a programmed cell death [33] . Thus, it is a challenge for immunologists to develop an effective and safe leptospirosis vaccine [34] [35] [36] [37] . Currently, molecular and cellular studies on leptospirosis vaccines have been focused on bacterial motility [38, 39] , lipopolysaccharides (LPSs) [10, [40] [41] [42] [43] [44] [45] [46] [47] , lipoproteins [48] [49] [50] [51] [52] [53] [54] [55] [56] , outer-membrane proteins (OMPs) [52,53,57-62] and potential virulence factors [39,63-68]. However, it is still a lack of an extensive knowledge-based annotation of leptospirosis vaccines for the scientists working in the field of leptospirosis vaccines. It has inspired us to investigate the current developments of leptospirosis vaccines and to construct a database of the leptospirosis vaccines for incorporating the leptospirosis vaccine information into bioinformatics by using Microsoft SQL server technology and intelligent algorithms (see section 6 and website [69]). Here, we classified the leptospirosis vaccines into recombinant protein vaccines, lipopolysaccharide (LPS) vaccines, inactivated and attenuated vaccines, and DNA vaccines for reviewing the current advancements in leptospirosis vaccine research. Several leptospiral outer membrane proteins, e.g. LAg42, Loa22, Lk73.5, have been recognized as leptospirosis vaccine candidates, but they were not tested in animal models for vaccine development. LAg42 is a 42 kDa innermembrane protein. It was identified in pathogenic Leptospira as a factor involved in virulence [83] . Loa22 was found among pathogenic leptospires but not in non-pathogenic leptospires. It is located in the outer membrane and exposed on the cell surface. It has been considered as a candidate for a novel vaccine against leptospirosis [49]. Lk73.5 is a host-inducible immunogenicity protein from pathogenic L. interrogans [72] . Although the protective characteristics of LAg42, Loa22 and Lk73.5 are not available, we believe these outer membrane proteins might be suitable as vaccine candidates. Lipoproteins are important proteins in leptospires. These proteins are abundant in the outer membrane, to which they are attached through fatty acids. Because of difficulty in production of lipoproteins in heterologous expression systems, only LipL41 was reported as a potential vaccine. However, many lipoproteins (for example: LipL32, LipL45 and LipL21) could be suitable as vaccine candidates. LipL32 [52] and LipL41 were identified as targets during natural infection by leptospires [37] . They are potentially useful for serodiagnosis and may serve as targets for vaccine design. LipL45 [67] and LipL21 [50] were described as surface membrane lipoproteins that are produced during infection and conserved among pathogenic Leptospira species. LipL45 is produced as a 45-kDa lipoprotein and it is processed to a 31-kDa C-terminal form, Moreover, the lipoprotein-like complex glycolipoproteins (GLPs) were suggested as vaccine candidates. A glycolipoprotein (GLP) extracted from either pathogenic L. interrogans or nonpathogenic L. biflexa was shown to induce production of the tumor necrosis factor, interleukin-10 and CD69 [85] . Obviously, the reported lipoproteins (LipL32, LipL45, LipL21 and GLP) are leptospirosis vaccine candidates. On the other hand, lipoprotein LipL36 was found not suitable as leptospirosis vaccine. LipL36 is a 36 kDa leptospiral outer membrane lipoprotein [54], which is synthesized at 30°C, but not at 37°C in vivo [84, 86] . Production of this protein was downregulated in hostadapted leptospires, suggesting that it is not involved in pathogenesis after entry into the mammalian host [62]. The virulence factor Hsp58 is a major target for the vaccine design [88] . The virulence factor hemolysin SphH is a pore-forming protein on several mammalian cells. The immune serum against the full-length hemolysin can effectively neutralize the SphH-mediated hemolytic and cytotoxic activities. SphH is required for pore formation in mammalian cell membranes and cytotoxic activities to mammalian cells [89, 90] . The virulence factor ChpK is encoded by L. interrogans chp locus, which consists of two genes: chpK and chpI. Expression of chpK in Escherichia coli results in inhibition of bacterial growth. Coexpression of chpI neutralizes ChpK toxicity. The chp locus was found in all representative pathogenic strains of L. interrogans [91]. All virulence factors described above (Hsp58, FlaA, FlaB, SphH and ChpK) can be considered as candidates for leptospirosis vaccines. Only Lig, LipL41 and Hap1 proteins were approved as vaccines against Leptospira in animals. Many recently reported outer membrane proteins (LAg42, Loa22, Lk73.5), lipoproteins (LipL32, LipL45, LipL21 and GLP) and newly discovered virulence factors (Hsp58, FlaA, FlaB, SphH and ChpK) can help us to find more suitable vaccine candidates [1] [2] [3] [4] 8, 9, [11] [12] [13] 94] . Because the genomes of L. interrogans serovar Icterohaemorrhagiae Lai [63] and L. interrogans serovar Copenhageni [95] were reported, heterologous expression of leptospiral outer membrane proteins (OMPs) became possible and opened new possibilities for vaccine development [10] . The basic rout of large-scale screening of the leptospirosis vaccines is shown in Fig. 3 . Before recombinant protein vaccines against leptospirosis can be used for clinical application, extensive testing is required. Recombinant protein vaccines must be free of contaminations, they should be stable and safe, and easy to transport and store. It has been found that a LPS vaccine may be serovar-independent. For example, LPS vaccine prepared from L. biflexa serovar Patoc can effectively protect hamsters against L. interrogans serovar Manilae. In this case, the protective effect strongly depended on the dose and administration times of LPS vaccine prepared from L. biflexa serovar Patoc [104] . However, it was also reported that a LPS vaccine can be serovar-dependent; for example, LPS vaccines prepared from several different serovar strains could not induce a protective immune response in gerbils against the strains of different serovars [105] . Obviously, further studies are required to determine whether other LPS vaccines are serovar-dependent or -independent. If LPS vaccines are serovar-independent in different animals or human, it will make LPS vaccines more simple and efficient. In 1989, a pioneer research on leptospiral LPS vaccines was reported [44] . Immunization characteristics of LPSs and polysaccharide (PS) in hamsters were compared. When hamsters were immunized with leptospiral LPSs or Large-scale screening of the leptospirosis vaccines PS fraction from L. interrogans serovar Copenhageni, maximum titers were observed approximately 6 weeks after immunization. The protection was achieved by immunization with as little as 2.5 μg of LPS or PS [44] . The immune characteristics of LPS were compared with PS and immunoconjugate of PS and diphtheria toxoid (DT) in mice vaccinated with these compounds. The maximum agglutinin titers could be achieved at 6-10 weeks after vaccination with LPS or PS-DT conjugate. PS-DT gave antibody titers at least 10 times higher than those produced in response to LPS. Titers obtained in experiments with antigens of serovar Pomona were higher than those of serovar Hardjo [43] . The protective ability of LPS extracts were compared with the protein extracts in experiments in which leptospirosis was induced in gerbils [105] . Total extracts induced complete protection against homologous infections and partial protection against heterologous infections. LPS fractions only protected against homologous but not heterologous infections, whereas protein extracts caused a significant protection against both types of infections [105] . Moreover, an immunogenicity of oligosaccharide fraction from the LPS of L. interrogans serovar Pomona was reported [102] . The oligosaccharide was isolated by endoglycosidase H digestion and column chromatography purification. When conjugated to diphtheria toxoid, the oligosaccharide caused production of a significant amount of protective antibodies [102] . Several lipopolysaccharide-like substances (LSSs) were reported as Leptospira antigens [47, 106, 107] . LSS was extracted from L. interrogans with a chloroform-methanolwater solution and partially purified by silica gel column chromatography. This antigen exhibited a protective activity in hamsters infected with lethal doses of L. interrogans [106, 107] . Moreover, LLS extracted from L. interrogans by the hot phenol-water method could enhance the immunological response in vivo [47]. Since LPSs are major antigens involved in serological response [45], these molecules can be considered as candidates for serodiagnosis [41] . For example, although L. borgpetersenii subtype Hardjobovis and L. interrogans subtype Hardjoprajitno belong to different species, they are serologically indistinguishable, and thus classified as serovar Hardjo. This is because the LPSs of these subtypes are identical [103] . Hence, LPSs can be used not only as leptospirosis vaccines, but also as antigens for serodiagnostics. Although LPSs have been tested as leptospirosis vaccines for almost 20 years, and promising results have been obtained, there are still have many problems to be solved. Between others, details of compositions and structures of leptospiral LPSs have to be determined. The inactivated and attenuated vaccines have been reported for more than 50 years. Some inactivated or attenuated leptospirosis vaccines were successfully tested in cattle [108] [109] [110] [111] [112] [113] [114] [115] [116] and dog [7, 27, [117] [118] [119] [120] [121] [122] . Inactivated leptospirosis vaccines were also tested in human volunteers [12, [123] [124] [125] [126] . The sera from persons vaccinated with a bivalent whole cell inactivated vaccine of L. interrogans serovar Hardjo or serovar Pomona contained IgM specific to both serovars [125] . Although the only leptospirosis vaccine licensed for humans is being produced in Cuba since 2006, inactivated and attenuated vaccines still acquire considerable interests. They are especially suitable as veterinary vaccines. When dogs were vaccinated twice with such vaccines and infection with L. interrogans followed the second vaccination, a high rate of protection against L. interrogans was observed and duration of immunity was at least 1-year [127] . The efficiency of inactivated vaccine could be improved by adjuvant and vaccination frequency. A commercial inactivated leptospirosis vaccine (with adjuvant) induced a poor antibody production in cattle during preliminary vaccination. However, after booster vaccination, this vaccine caused a remarkable immune response [128] . Hydrostatic pressure-treated leptospires can be used as inactivated vaccine. After such leptospires were inoculated into rabbits, the vaccine was immunogenic [129] . The inactivated vaccine can induce a strong antigen-specific proliferative response by peripheral blood mononuclear cells (PBMC) of vaccinated cattle 2 months after the first dose of vaccine [130] . The results discussed above show that inactivated or attenuated vaccines are suitable as the leptospirosis vaccines [4, 5, [8] [9] [10] [11] 13] . However, such vaccines cause safety problems [131, 132] . DNA vaccines have been used against different diseases [133] . These vaccines have several advantages over recombinant protein vaccines. Namely, DNA vaccines have very simple processing routes [134, 135] , low prices [136] , and easy administration properties [137, 138] . In just a few years, DNA vaccine technology has been developed from an interesting observation to the practical application [139] [140] [141] . Surprisingly, only two leptospiral DNA vaccine trials have been reported. DNA vaccine encoding hemolysis-associated protein 1 (Hap1) was tested in gerbils, and partial protection against the infection by pathogenic strains of Leptospira was achieved [142] . Another example is the use of a DNA vaccine containing the endoflagellin gene flaB2 in experiments with guinea pigs [143] . Obviously, leptospirosis DNA vaccines need more exten-sive investigations. It will be very valuable to test the immune characteristics of multiple leptospirosis DNA vaccine complexes in animals. With the development of leptospirosis vaccines, it is now possible to construct a database for leptospirosis vaccines. We have constructed a leptospirosis vaccine ontology database, which is available at the website [69] . In this database, we have presented information on some important leptospirosis vaccines. Each vaccine in the database has an ontology value, obtained on the basis of the experimental results from particular report and expert evaluation. We believe that this database may be helpful for scientists working in the leptospirosis field, as well as for those working on bioinformatics. The information on vaccines can be transmitted to the bioinformatics field for vaccine classification, processing optimization and predicting of vaccine efficiency from amino acid sequences or compositions without experiments on animals. Vaccines are administered to a large number of healthy humans and animals to make them resistant to diseases, therefore, vaccines must be of high safety [144, 145] . There are two basic types of leptospirosis vaccines available, attenuated and inactivated leptospirosis vaccines. However, these two types of vaccines reveal significant safety problems. The attenuated vaccines were achieved by propagation of the microbe under conditions different from those in the infected host and, hopefully, unfavorable to its growth in the host. Obviously, this method could not guarantee enough safety. It requires many tests to ensure the safety, but the safety still remains an issue. A more rational approach to attenuate the microbe would be to inactivate leptospiral components or genes known to code virulence factors. For example, an attenuated leptospiral vaccine could be developed by elimination of the leptospiral O antigen. Analogously, inactivation of the LPS biosynthetic loci (rfb) might result in attenuation a leptospiral strain. Careful analysis of genes coding for the virulence factors of Leptospira should allow us to construct attenuated strains for leptospirosis vaccines. Inactivated leptospirosis vaccines were extensively investigated during 70-80s' of 20 th century. The major problems concerned both their safety and efficacy. It appears that a combination of attenuated and inactivated leptospirosis vaccine may be highly effective. New attenuated vaccines should be designed on the basis of our knowledge about sequences of genomes and virulence determinants of the pathogens to maximize their safety. A real breakthrough for leptospirosis vaccines was the genetic technology that allows expression of leptospiral genes in heterologous organisms. In fact, many outer membrane proteins have been obtained, which are candidates for vaccines [58] . The advantages of production of recombinant vaccine antigens in a selected heterologous host organism arises from simplicities of cultivation of the host and purification of recombinant proteins. Furthermore, recombinant proteins are useful as antigens in immunoassays to detect leptospires. It has been reported that leptospirosis vaccines with adjuvant were more immunogenic than those without adjuvant [146] . Thus, it appears that more research is required to develop novel adjuvants for leptospirosis vaccines, like recently described bacterial tRNA adjuvant [147] and cdiGMP adjuvant [140] . Increasing attention is being devoted to the fact that infections of leptospires are naturally acquired through mucosa. Administering the vaccines by the mucosal route [148] [149] [150] [151] [152] , oral route [153] [154] [155] [156] , nasal spray [157] , or through topical application on the skin would be welcome [138] . The optimal formulations, adjuvants, doses and schedules are crucial for vaccine efficacy [127, 158] . The idea to produce leptospiral antigens as protein components of edible plants is indeed feasible, and the idea of the combination of leptospirosis vaccines and drugs to cure leptospirosis is very interesting [6, 8, 9, 158 ]. An improvement of quality of DNA vaccines and recombinant protein vaccines appears to be important for the practical application [135, [159] [160] [161] . Moreover, we believe that construction of a web service, like the leptospirosis vaccine ontology database, would be important for scientists working on leptospirosis vaccines. The author(s) declare that they have no competing interests. All authors have contributed to the content of the article. Peru-United States Leptospirosis Consortium: Leptospirosis: a zoonotic disease of global importance Current status of leptospirosis in Japan and Philippines Leptospirosis: pathogenesis, immunity, and diagnosis Prospects of developing leptospiral vaccines for animals Optimal treatment of leptospirosis: queries and projections Canine leptospirosis -do we have a problem? Leptospirosis vaccines: past, present, and future Technological advances in the molecular biology of Leptospira Overview of the epidemiology, microbiology, and pathogenesis of Leptospira spp. in humans Review on human leptospirosis Current status of leptospiral vaccines Weil's syndrome in a zoologist Cell aggregation: a mechanism of pathogenic Leptospira to survive in fresh water Leptospirosis in Kolenchery, Kerala, India: epidemiology, prevalent local serogroups and serovars and a new serovar Leptospirosis as an occupational disease Leptospira inadai" serovar lyme) isolated from human skin Leptospirosisinduced meningitis and acute renal failure in a 19-month-old male child Leptospiral pneumonias Pulmonary leptospirosis Chronic hepatitis associated with leptospiral infection in vaccinated beagles Risk factors for death and changing patterns in leptospirosis acute renal failure Renal leptospirosis: challenge exposure to vaccinated and nonvaccinated cattle to Leptospira icterohaemorrhagiae and Leptospira canicola Prevention of renal infection and urinary shedding in dogs by a Leptospira vaccination Prevention of renal carriage of leptospirosis in dogs by vaccination Acute pancreatitis in fatal anicteric leptospirosis Leptospirosis as a cause of erythema nodosum Assessment of the clinical presentation and treatment of 353 cases of laboratory-confirmed leptospirosis in Hawaii epidemiological, clinical, and serological features Rapid translocation of polarized MDCK cell monolayers by Lepttein, FlaB, from Leptospira interrogans by N-terminal sequencing, gene cloning, and sequence analysis Leptospirosis in dogs: a serologic survey and case series Genome features of Leptospira interrogans serovar Copenhageni Genetic differences among the LPS biosynthetic loci of serovars of Leptospira interrogans and Leptospira borgpetersenii Functional analysis of genes in the rfb locus of Leptospira borgpetersenii serovar Hardjo subtype Hardjobovis Genetic organization of the lipopolysaccharide O-antigen biosynthetic locus of Leptospira borgpetersenii serovar Hardjobovis Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism A methylated phosphate group and four amide-linked acyl chains in leptospira interrogans lipid A. The membrane anchor of an unusual lipopolysaccharide that activates TLR2 Experimental immunization of hamsters with an EDTA extract of Leptospira interrogans, serovar icterohaemorrhagiae Characterization of an antigenic oligosaccharide from Leptospira interrogans serovar pomona and its role in immunity Comparative analysis of the LPS biosynthetic loci of the genetic subtypes of serovar Hardjo: Leptospira interrogans subtype Hardjoprajitno and Leptospira borgpetersenii subtype Hardjobovis Control of immunologically crossreactive leptospiral infection by administration of lipopolysaccharides from a nonpathogenic strain of Leptospira biflexa Evidence of cross-protection within Leptospira interrogans in an experimental model Immunological characteristics of the glycolipid antigen of Leptospira interrogans serovar lai Comparison of protective effects with tetra-valent glycolipid antigens and whole cellinactivated vaccine in experimental infection of Leptospira An experience with a Leptospira pomona bacterin in dairy cattle The effect of revaccination of horses and cattle with Leptospira pomona bacterin An immunogenic agent for the protection of cattle against Leptospira pomona Comparison of Leptospira pomona bacterin and attenuated live culture vaccine for control of abortion in cattle Current status of leptospirosis immunization in swine and cattle Vaccination for reproductive efficiency in cattle Immunity to leptospirosis: Leptospira interrogans serotype pomona bacterins in cattle Evaluation of the immune response of cattle to single and multiple vaccination with a polyvalent leptospiral bacterin Serology in cattle vaccinated with leptospirosis bacterins. Mod Vet Pract Early protection of dogs by a leptospira bacterin Immunity to leptospirosis: bacterins in dogs and hamsters Experiements with an inactivated hepatitis leptospirosis vaccine in vaccination programmes for dogs Experiments with a homologous, inactivated canine parvovirus vaccine in vaccination programmers for dogs Combined viral and bacterial antigens for canine vaccines Canine leptospirosis infections -clinical signs and outcome with different suspected Leptospira serogroups (42 cases) A new leptospiral vaccine for use in man. I. Development of a vaccine from Leptospira grown on a chemically defined medium A new leptospiral vaccine for use in man. II. Clinical and serologic evaluation of a field trial with volunteers Antigens recognized by the human immune response to vaccination with a bivalent hardjo/pomona leptospiral vaccine Immunogenicity of boiled compared with formalized leptospiral vaccines in rabbits, hamsters and humans Duration of immunity in dogs vaccinated against leptospirosis with a bivalent inactivated vaccine Enhanced antibody response in cattle against Leptospira hardjo by intradermal vaccination Effects of hydrostatic pressure on the Leptospira interrogans: high immunogenicity of the pressure-inactivated serovar hardjo Protective killed Leptospira borgpetersenii vaccine induces potent Th1 immunity comprising responses by CD4 and gammadelta T lymphocytes Overview of vaccines Vaccines and infectious disease Cui Z: DNA vaccine Gene-based vaccines: recent technical and clinical advances Processing of plasmid DNA with ColE1-like replication origin Littel-van den H: Nucleic acid vaccines: research tool or commercial reality Human clinical trials of plasmid DNA vaccines Topical application of plasmid DNA to mouse and human skin Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant DNA vaccines: successes and limitations in cancer and infectious disease Protection against Leptospira interrogans sensu lato challenge by DNA immunization with the gene encoding hemolysin-associated protein 1 Protection against leptospirosis by immunization with plasmid DNA encoding 33 kDa endoflagellin of L. interrogans serovar lai Van Damme P: Vaccine safety controversies and the future of vaccination programs Vaccine side effects: fact and fiction Improving vaccines by incorporating immunological coadjuvants. Expert Rev Vaccines The 3' CCACCA sequence of tRNA Ala (UGC) is the motif that is important in inducing Th1-like immune response, and this motif can be recognized by Toll-like receptor 3 Implication of nanoparticles/microparticles in mucosal vaccine delivery Mucosal vaccine development for botulinum intoxication Mucosal delivery of vaccine antigens and its advantages in pediatrics Mucosal immunity induced by pneumococcal glycoconjugate Mechanisms of vaccine adjuvanticity at mucosal surfaces The biology of oral tolerance and issues related to oral vaccine design A rice-based edible vaccine expressing multiple Tcell epitopes to induce oral tolerance and inhibit allergy Microparticles for oral delivery of vaccines A revisit of mucosal IgA immunity and oral tolerance Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery Thoughts on leptospirosis vaccines Effects of the presence of ColE1 plasmid DNA in Escherichia coli on the host cell metabolism Recombinant protein production in the new Millennium. Microbial Cell Fact Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli We thank Professor Grzegorz Wegrzyn for discussions. This work was supported by National Natural Science Foundation of China (Grant Number: 30400077) and by Institute of Biochemistry and Biophysics of the Polish Academy of Sciences (task grant 32.1).